Lakewood-Amedex Biotherapeutics, Inc.
LABT
$3.14
-$0.34-9.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 89.24% | 22.60% | 203.89% | -12.66% | -33.38% |
| Depreciation & Amortization | 0.00% | 0.00% | -14.29% | -29.41% | -40.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.44% | -17.41% | 105.97% | -42.60% | -52.46% |
| Operating Income | -63.44% | 17.41% | -105.97% | 42.60% | 52.46% |
| Income Before Tax | -71.11% | 12.83% | 1.49% | 38.16% | 46.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.11% | 12.83% | 1.49% | 38.16% | 46.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.11% | 12.83% | 1.49% | 38.16% | 46.26% |
| EBIT | -63.44% | 17.41% | -105.97% | 42.60% | 52.46% |
| EBITDA | -63.55% | 17.43% | -106.17% | 42.62% | 52.47% |
| EPS Basic | -36.14% | 4.17% | 1.84% | 38.22% | -1.92% |
| Normalized Basic EPS | -69.84% | 13.13% | -112.83% | 38.22% | 46.75% |
| EPS Diluted | -36.14% | 4.17% | 1.84% | 38.22% | -1.92% |
| Normalized Diluted EPS | -69.84% | 13.13% | -112.83% | 38.22% | 46.75% |
| Average Basic Shares Outstanding | 0.75% | 0.36% | 0.36% | 0.10% | 0.92% |
| Average Diluted Shares Outstanding | 0.75% | 0.36% | 0.36% | 0.10% | 0.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |